Brian Zeglis, PhD

Publications

100

4 grants

PI
Providing GMP-grade Terbium-161 as a therapeutic option for US academic institution
NCI · 2025–2028 · via NIH RePORTER
R44CA295134-01A1
MPI
ImmunoPET Probes for the Imaging of Lyme Disease
NIAID · 2023–2028 · via NIH RePORTER
R01AI175417-04
PI
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer
NCI · 2023–2028 · via NIH RePORTER
R01CA281801-04
PI
The Development of Radiotherapeutic Paradigms for Desmoplastic Small Round Cell Tumor
NCI · 2026–2028 · via NIH RePORTER
R21CA309945-01

Completed grants (8)

MPI
Targeting DNA Mismatches for Auger Electron Radiotherapy
NCI · 2023–2025 · via NIH RePORTER
R21CA280595-01A1
PI
Novel Reagents for Rapid and Stable Thiol-Based Bioconjugations
NCI · 2019–2025 · via NIH RePORTER
R01CA240963-05
MPI
Pretargeted Clinical Imaging of CA19.9 in Pancreatic Cancer
NCI · 2018–2024 · via NIH RePORTER
U01CA221046-05
MPI
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab
NCI · 2016–2023 · via NIH RePORTER
R01CA204167-05
MPI
A PET Radiotracer for Diagnostic and Theranostics Imaging in Lyme Disease
NIBIB · 2020–2022 · via NIH RePORTER
R21EB030275-02
PI
Pretargeted Radioimmunotherapy Based on Bioorthogonal Click Chemistry
NCI · 2014–2018 · via NIH RePORTER
R00CA178205-04
PI
Pretargeted Radioimmunotherapy Based on Bioorthogonal Click Chemistry
NCI · 2014–2015 · via NIH RePORTER
K99CA178205-01A1
PI
PET Imaging of Topoisomerase-II Expression in Breast Cancer
NCI · 2009–2012 · via NIH RePORTER
F32CA144138-03